Is Summit Therapeutics Inc. (SMMT) a Buy, Sell, or Hold?
Summit Therapeutics Inc.
NASDAQ:SMMT
$15.07 USD
-$0.4 (-2.59%)
- Volume
- 2.3M
- Average Volume
- 5.54M
- Market Capitalization
- $11.7B
- P/E Ratio
- -10.76
- Dividend Yield
- 0.00%
- Price Target
- $19.50
- Year High
- $30.98
- Year Low
- $12.55
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.41
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Robert W. Duggan |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | SMMT |
| CUSIP | 86627T108 |
| CIK | 0001599298 |
| Web | https://www.smmttx.com |
| Phone | 617 514 7149 |
| Currency | USD |
| Employees | 265 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.41 |
| Quick Ratio | 7.41 |
| Cash Ratio | 1.28 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.37 |
| Price / Cash Flow | -40.77 |
| Price / Book | 28.23 |
Price Target and Rating
| Average Stock Price Forecast | $19.50 |
| High Stock Price Forecast | $23.00 |
| Low Stock Price Forecast | $16.00 |
| Forecast Upside/Downside | -22.72% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 21 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.44 |
| Trailing P/E Ratio | -10.76 |
| PEG Ratio | 0.08 |
| P/E Growth | 0.08 |
| Net Income | $-1.08B |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -340.55% |
| Return on Assets | -214.23% |
Financials Score
| AltmanZ Score | 57.93 |
| Piotroski Score | 1.00 |
| Working Capital | 404.46M |
| Total Assets | 491.31M |
| Ebit | -1.05B |
| Market Cap | 8.94B |
| Total Liabilities | 77.3M |
Poll Results
About Summit Therapeutics Inc. (NASDAQ:SMMT) Stock
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caus ... ed by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
2026-07-15 09:51:05
SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
2026-07-14 08:00:00
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigat
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
2026-07-14 07:00:00
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificial intelligence (AI)-native biopharma company focused on advancing late-stage programs in life-threatening indications with urgent unmet medical needs. Previously, ridinilazole was evaluated in Summit's Phase III Ri-CoDIFy study for the tre.
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-30 07:45:03
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet
2026-06-22 09:05:03
Summit Therapeutics is a highly volatile, single-asset company with a binary outcome. SMMT exhibits unusually concentrated ownership and heightened short interest, creating conditions for a short squeeze to take place. Recent pullbacks, driven by mixed market receptions to events do not fundamentally alter the investment narratives, present investors with an attractive entry point ahead of key catalysts.
Summit Therapeutics Announces Proposed Public Offering of Common Stock
2026-06-09 16:47:00
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price, less underwriting discounts and c.
2026-06-08 15:08:30
Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
2026-06-07 09:30:55
After years of lagging the market, healthcare may be taking on a new role in investor portfolios.
Frequently Asked Questions
-
What is the current Summit Therapeutics Inc. (SMMT) stock price?
-
Summit Therapeutics Inc.(NASDAQ:SMMT) stock price is $15.07 in the last trading session. During the trading session, SMMT stock reached the peak price of $30.98 while $12.55 was the lowest point it dropped to. The percentage change in SMMT stock occurred in the recent session was --2.59% while the dollar amount for the price change in SMMT stock was -$-0.4.
-
SMMT's industry and sector of operation?
-
The NASDAQ listed SMMT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SMMT?
-
Bilal Piperdi | Chief Medical Officer
Elaine Carla Stracker | Chief Legal Officer
Howard Jack West | Vice President of Clinical Development
Mahkam Zanganeh | Co-CEO, President & Director
Bhaskar Anand | Chief Accounting Officer & Head of Finance -
How many employees does SMMT have?
-
Number of SMMT employees currently stands at 265. SMMT operates from One Broadway, Cambridge, MA 02142, US.
-
Link for SMMT official website?
-
Official Website of SMMT is: https://www.smmttx.com
-
How do I contact SMMT?
-
SMMT could be contacted at phone #617 514 7149 and can also be accessed through its website. SMMT operates from One Broadway, Cambridge, MA 02142, US.
-
How many shares of SMMT are traded daily?
-
The average number of SMMT shares traded daily for last 3 months was 5.54M.
-
What is the market cap of SMMT currently?
-
The market value of SMMT currently stands at $11.7B with its latest stock price at $15.07